Literature DB >> 21700688

Systemic vascular dysfunction in patients with chronic mountain sickness.

Stefano F Rimoldi1, Emrush Rexhaj1, Lorenza Pratali2, Damian M Bailey3, Damian Hutter4, Francesco Faita2, Carlos Salinas Salmòn5, Mercedes Villena5, Pascal Nicod6, Yves Allemann4, Urs Scherrer7, Claudio Sartori8.   

Abstract

BACKGROUND: Chronic mountain sickness (CMS) is a major public health problem characterized by exaggerated hypoxemia and erythrocytosis. In more advanced stages, patients with CMS often present with functional and structural changes of the pulmonary circulation, but there is little information on the systemic circulation. In patients with diseases associated with chronic hypoxemia at low altitude, systemic vascular function is altered. We hypothesized that patients with CMS have systemic vascular dysfunction that may predispose them to increased systemic cardiovascular morbidity.
METHODS: To test this hypothesis, we assessed systemic endothelial function (by flow-mediated dilation [FMD]), arterial stiffness, and carotid intima-media thickness and arterial oxygen saturation (Sao(2)) in 23 patients with CMS without additional classic cardiovascular risk factors and 27 age-matched healthy mountain dwellers born and permanently living at 3,600 m. For some analyses, subjects were classified according to baseline Sao(2) quartiles; FMD of the highest quartile subgroup (Sao(2) ≥ 90%) was used as a reference value for post hoc comparisons.
RESULTS: Patients with CMS had marked systemic vascular dysfunction as evidenced by impaired FMD (CMS, 4.6% ± 1.2%; control subjects, 7.6% ± 1.9%; P < .0001), greater pulse wave velocity (10.6 ± 2.1 m/s vs 8.4 ± 1.0 m/s, P < .001), and greater carotid intima-media thickness (690 ± 120 μm vs 570 ± 110 μm, P = .001). A positive relationship existed between Sao(2) and FMD (r = 0.62, P < .0001). Oxygen inhalation improved (P < .001) but did not normalize FMD in patients with CMS, although it normalized FMD in hypoxemic control subjects (Sao(2) < 90%) and had no detectable effect in normoxemic control subjects (Sao(2) ≥ 90%).
CONCLUSIONS: Patients with CMS show marked systemic vascular dysfunction. Structural and functional alterations contribute to this problem that may predispose these patients to premature cardiovascular disease. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01182792; URL: www.clinicaltrials.gov.

Entities:  

Mesh:

Year:  2011        PMID: 21700688     DOI: 10.1378/chest.11-0342

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  19 in total

1.  Left ventricular adaptation to high altitude: speckle tracking echocardiography in lowlanders, healthy highlanders and highlanders with chronic mountain sickness.

Authors:  Chantal Dedobbeleer; Alia Hadefi; Aurelien Pichon; Francisco Villafuerte; Robert Naeije; Philippe Unger
Journal:  Int J Cardiovasc Imaging       Date:  2015-02-10       Impact factor: 2.357

Review 2.  Prevalence of hypertension and its relationship with altitude in highland areas: a systematic review and meta-analysis.

Authors:  Xin Zhang; Zhipeng Zhang; Runyu Ye; Qingtao Meng; Xiaoping Chen
Journal:  Hypertens Res       Date:  2022-06-15       Impact factor: 5.528

Review 3.  High-Altitude Erythrocytosis: Mechanisms of Adaptive and Maladaptive Responses.

Authors:  Francisco C Villafuerte; Tatum S Simonson; Daniela Bermudez; Fabiola León-Velarde
Journal:  Physiology (Bethesda)       Date:  2022-01-10

4.  Conduit artery structure and function in lowlanders and native highlanders: relationships with oxidative stress and role of sympathoexcitation.

Authors:  Nia C S Lewis; Damian M Bailey; Gregory R Dumanoir; Laura Messinger; Samuel J E Lucas; James D Cotter; Joseph Donnelly; Jane McEneny; Ian S Young; Mike Stembridge; Keith R Burgess; Aparna S Basnet; Philip N Ainslie
Journal:  J Physiol       Date:  2013-12-09       Impact factor: 5.182

Review 5.  Measuring high-altitude adaptation.

Authors:  Lorna G Moore
Journal:  J Appl Physiol (1985)       Date:  2017-08-31

6.  Global Reach 2018 Heightened α-Adrenergic Signaling Impairs Endothelial Function During Chronic Exposure to Hypobaric Hypoxia.

Authors:  Michael M Tymko; Justin S Lawley; Philip N Ainslie; Alexander B Hansen; Florian Hofstaetter; Simon Rainer; Sachin Amin; Gilbert Moralez; Christopher Gasho; Gustavo Vizcardo-Galindo; Daniela Bermudez; Francisco C Villafuerte; Christopher M Hearon
Journal:  Circ Res       Date:  2020-04-09       Impact factor: 17.367

7.  Vascular endothelial growth factor-A is associated with chronic mountain sickness in the Andean population.

Authors:  Jose R Espinoza; Giancarlo Alvarez; Fabiola León-Velarde; Hugo F Ju Preciado; Jose-Luis Macarlupu; Maria Rivera-Ch; Jorge Rodriguez; Judith Favier; Anne-Paule Gimenez-Roqueplo; Jean-Paul Richalet
Journal:  High Alt Med Biol       Date:  2014-06       Impact factor: 1.981

8.  Global REACH 2018: dysfunctional extracellular microvesicles in Andean highlander males with excessive erythrocytosis.

Authors:  L Madden Brewster; Anthony R Bain; Vinicius P Garcia; Hannah K Fandl; Rachel Stone; Noah M DeSouza; Jared J Greiner; Michael M Tymko; Gustavo A Vizcardo-Galindo; Romulo J Figueroa-Mujica; Francisco C Villafuerte; Philip N Ainslie; Christopher A DeSouza
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-03-12       Impact factor: 4.733

9.  Endothelial markers in high altitude induced systemic hypertension (HASH) at moderate high altitude.

Authors:  Uday Yanamandra; S P Singh; Sushma Yanamandra; Deepak Mulajkar; R S Grewal; Shashibala Singh; M Z Ashraf; Prasanna Reddy; Velu Nair
Journal:  Med J Armed Forces India       Date:  2017-11-15

10.  Prevalence, clinical profile, iron status, and subject-specific traits for excessive erythrocytosis in andean adults living permanently at 3,825 meters above sea level.

Authors:  Aldo De Ferrari; J Jaime Miranda; Robert H Gilman; Victor G Dávila-Román; Fabiola León-Velarde; Maria Rivera-Ch; Luis Huicho; Antonio Bernabé-Ortiz; Robert A Wise; William Checkley
Journal:  Chest       Date:  2014-11       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.